NCT06081387

Brief Summary

The purpose of this study protocol is to assess the effect of concurrent aerobic and resistance training in patients with type 2 diabetes on vitamin D treatment

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable diabetes-mellitus-type-2

Timeline
19mo left

Started Oct 2025

Typical duration for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress28%
Oct 2025Dec 2027

First Submitted

Initial submission to the registry

July 6, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

October 13, 2023

Completed
2 years until next milestone

Study Start

First participant enrolled

October 1, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Expected
Last Updated

August 6, 2025

Status Verified

May 1, 2025

Enrollment Period

3 months

First QC Date

July 6, 2023

Last Update Submit

August 1, 2025

Conditions

Keywords

Vitamin DAerobic trainingResistance trainingInsulin resistance

Outcome Measures

Primary Outcomes (9)

  • Change in Homeostatic Model Assessment of Insulin Resistance (HOMA IR)

    HOMA-IR index will be calculated by using formula (HOMA-IR=fasting glucose in mmol/l\*fasting insulin in μU/ml/22.5) to determine insulin resistance

    Beginning of the study and after 4 months

  • Change in Homeostasis model assessment of β-cell function (HOMA-β)

    The HOMA-B index will be used to quantify the pancreatic beta cells function (HOMA-B360 x fasting insulin (μU/mL) / (fasting glucose (mg/dL) - 63)).

    Beginning of the study and after 4 months

  • Change in serum levels of Hemoglobin A1c.

    Serum levels of hemoglobin A1c will be tested in the laboratory from blood draws conducted at initial visit from a fasting blood sample.

    Beginning of the study and after 4 months

  • Change in serum lipid profile

    Total cholesterol and High-density lipoprotein (HDL) cholesterol and triglyceride levels (mg/dL). Analysis ill be performed by the fully automatic Mindray BS380 using photometry-fixed time and point turbidimetry.

    Beginning of the study and after 4 months

  • Change in weight

    Anthropometric measurements (weight in kilograms)

    Beginning of the study and after 4 months

  • Change in waist circumference

    Anthropometric measurements (waist circumference in centimetre)

    Beginning of the study and after 4 months

  • Change in Body Mass Index (BMI)

    (BMI \[weight and height will be combined to report BMI\] in kg/m2

    Beginning of the study and after 4 months

  • Vitamin D

    Determination of Vitamin D levels in blood (ng/mL)

    Beginning of the study

  • Vitamin D

    Determination of Vitamin D levels in blood (ng/mL)

    End of the study (4 Months)

Secondary Outcomes (7)

  • Sociodemographic data

    Beginning of the study

  • Activity degree

    Beginning of the study

  • Activity degree

    End of the study (4 Months)

  • Psychological Well-being

    Beginning of the study

  • Psychological Well-being

    End of the study (4 Months)

  • +2 more secondary outcomes

Study Arms (4)

Vitamin D treatment and training

EXPERIMENTAL

Subjects are type 2 diabetic patients on vitamin D treatment that will recieve a sarcoplasma stimulating training program. This program will run for 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods and a familiarization week session. In the first intervention week, the movements are as follows: 4 sets of eight repetitions with 20 seconds interval of rest between sets will be performed, with 60% of maximum repetitions. In the second week, with increasing intensity, the exercise will be performed with 60% 1RM. The third week, each movement will be performed in 5 sets with 6 repetitions with 20 seconds of rest between Hursts as an interval with 60% of maximum repetitions.

Other: Resistance training

No vitamin D and training

ACTIVE COMPARATOR

This will include type 2 diabetic patients not being treated with vitamin D. Sarcoplasm stimulating training system will be performed. This program will run for 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session. In the first week of intervention, the movements are as follows: 4 sets of eight repetitions with 20 seconds interval of rest between sets will be performed, with 60% of maximum repetitions. In the second week, with increasing intensity, the exercise will be performed with 60% 1RM. The third week, each movement will be performed in 5 sets with 6 repetitions with 20 seconds of rest between Hursts as an interval with 60% of maximum repetitions.

Other: Resistance training

Vitamin D treatment and no traininig

NO INTERVENTION

Subjects are type 2 diabetic patients on vitamin D treatment. In this group, no exercise program will be performed.

No Vitamin D and no training

NO INTERVENTION

Subjects are type 2 diabetic patients with no vitamin D treatment and no exericse program

Interventions

Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.

Also known as: Sarcoplasm stimulating training system, exercise.
No vitamin D and trainingVitamin D treatment and training

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (females or males) older than 18 years old with a diagnosis of T2D in the clinic database
  • Patients who have been taking the combination therapy of metformin + sodium-glucose transport protein 2 inhibitors (iSGLT2), as recommended by the redGDPS 2023, with stable medication for the past 6 months.
  • Diabetic patients taking prescribed VitD treatment for at least 6 months (intervention group) and diabetic patients not taking prescribed VitD (control group)
  • Patients who signed the informed consent
  • Patients capable of performing mild to moderate physical activity (to walk steadily and independently for at least 6 minutes)

You may not qualify if:

  • Patients taking other medication different than metformin + iSGLT2 (including combinations and insulin)
  • Female subjects who are pregnant
  • Patients who did not sign the informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CAP Sant Rafael

Barcelona, Spain

RECRUITING

Related Publications (1)

  • Dardashtipour E, Canivell S, Azarbayjani MA, Fuente-Vidal A, Surroca A, Gascon P, Mestres C, Anton A, Pena-Mateo MJ, Carrillo-Alvarez E, Canudas AM, Guerra-Balic M, Montane J. The effect of aerobic and resistance training in patients with type 2 diabetes on vitamin D (DIAVITEX): a study protocol. Front Public Health. 2026 Jan 5;13:1674293. doi: 10.3389/fpubh.2025.1674293. eCollection 2025.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Insulin Resistance

Interventions

Resistance TrainingExercise

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesHyperinsulinism

Intervention Hierarchy (Ancestors)

Exercise TherapyRehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy ModalitiesPhysical Conditioning, HumanMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Joel Montane, PhD

    Universitat Ramon Llull

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Joel Montane, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 6, 2023

First Posted

October 13, 2023

Study Start

October 1, 2025

Primary Completion

January 1, 2026

Study Completion (Estimated)

December 31, 2027

Last Updated

August 6, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations